Additional benefits include increased buprenorphine initiation, decreased methadone initiation, and improved buprenorphine retention
The centrally acting alpha2-adrenergic agonist is approved for patients ≥6 years
Study finds reduction in impulsive-reactive behavior-related crimes but not those with intent or planning
Although most effective for symptoms, medications are also tied to adverse effects
Risk for cardiomyopathy increased with duration of treatment for adults aged 20 to 40 years with ADHD
Reduced risk for psychiatric, nonpsychiatric hospitalization seen with use of ADHD meds among adolescents, adults with ADHD
Differences in motor skills, sensory and autism features, but not ADHD features, impact daily living skills in children with autism
Significantly lower rates seen for all-cause mortality and unnatural-cause mortality, but not natural-cause mortality
However, adults with ADHD score lower than those with autism on total camouflaging and subscales